Compare Biogen Inc (BIIB) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs IONQ Inc — how do they compare? Biogen Inc trades at $196.33 (market cap $28.34B), while IONQ Inc trades at $37.68 (market cap $14.67B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | IONQ | |
|---|---|---|
Market Cap | $28.34B | $14.67B |
Sector | Health | Technology |
52-Week High | $216.63 | $82.09 |
52-Week Low | $122.68 | $26.59 |
Enterprise Value | $30.62B | $12.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
IONQ shares declined 9.29% to $38.88 amid broader quantum computing sector weakness, though technical indicators show oversold conditions with RSI at 16.05. The company maintains a mixed fundamental picture with strong revenue growth projections ($130M in 2025 to $187M in 2026) but significant operating losses. Analyst sentiment remains divided with a 50/50 buy/hold split despite a consensus price target of $73.75 representing 90% upside potential from current levels.
The stock presents high-risk, high-reward potential with Wall Street recognizing IONQ's leadership in trapped-ion quantum computing technology but concerned about cash burn and execution risks. Near-term catalysts include Q2 2026 earnings and the planned 256-qubit system demonstration, though the stock faces volatility from speculative trading and competitive pressures in the emerging quantum sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
